Study of 177Lu-INN805 for advanced solid tumors
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This trial tests a new treatment called 177Lu-INN805 for people with advanced solid tumors that have not responded to standard therapies. It aims to see if the drug is safe, where it goes in the body, and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have an advanced solid tumor that has stopped responding to standard treatments.
- You have at least one tumor that can be measured on scans.
- You are able to handle daily activities with little or no help (ECOG score 0 or 1).
- Your blood counts and liver and kidney function are within certain ranges.
- You have not had cancer treatment or major surgery in the last 4 weeks, and side effects from past treatments have mostly gone away.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.